There are 40 resources available
Live Q&A and discussion
Presenter: All Speakers
Session: Best of abstracts session
Resources:
Webcast
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation
Presenter: Andres Maria Poveda Velasco
Session: Best of abstracts session
Resources:
Slides
Webcast
Current and emerging biomarkers in recurrent OvCa
Presenter: Susana Banerjee
Session: Treatment and biomarkers of recurrent ovarian cancer: Where are we in 2021 and what’s next?
Resources:
Slides
Webcast
Do all patients with recurrent ovarian cancer need systemic therapy and which is the optimal treatment algorithm?
Presenter: MICHAEL FRIEDLANDER
Session: Treatment and biomarkers of recurrent ovarian cancer: Where are we in 2021 and what’s next?
Resources:
Slides
Webcast
Live Q&A and discussion
Presenter: All Speakers
Session: Treatment and biomarkers of recurrent ovarian cancer: Where are we in 2021 and what’s next?
Resources:
Webcast
No
Presenter: Kathleen Moore
Session: Immunotherapy in ovarian cancer: Is there a future in clinical practice?
Resources:
Slides
Webcast
Second vote and live conclusions
Presenter: All Speakers
Session: Immunotherapy in ovarian cancer: Is there a future in clinical practice?
Resources:
Slides
Webcast
Live introduction and first vote
Presenter: Robert Coleman
Session: Immunotherapy in ovarian cancer: Is there a future in clinical practice?
Resources:
Slides
Webcast
Yes
Presenter: Eric Pujade-Lauraine
Session: Immunotherapy in ovarian cancer: Is there a future in clinical practice?
Resources:
Webcast
Live closing remarks by the Scientific Co-Chairs
Presenter: All Speakers
Session: Closing remarks
Resources:
Webcast